Cue Biopharma(CUE) - 2023 Q4 - Annual Report

✓ Generation of a Therapeutic Index for IL-2 > Selective targeting of IL-2 to tumor-specific T cells ✓ Clinical Validation and PoC (>100 Patients Treated) > Monotherapy activity in late-stage cancer patients > Potential doubling of ORR and mPFS in combination with CPI ์ Favorable Tolerability Profile ✓ Strong Metrics of Manufacturability Flexible Platform with Potential Regulatory Advantages The structural design of our IL-2 based CUE-100 series antibody-based molecules enables modularity of the various com ...